Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00911729 · ClinicalTrials.gov registry record
Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
A clinical trial, sponsored by Molecular Insight Pharmaceuticals.
- Terminated
- Registry status
- 24
- Enrollment target
NCT00911729 is a clinical trial that was terminated before completion, run by Molecular Insight Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT00911729 was terminated before completion, sponsored by Molecular Insight Pharmaceuticals.
- TERMINATED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The purpose of this qualitative study is to evaluate the clarity and comprehensiveness of two disease-specific questionnaires, and to evaluate how effective these questionnaires are at assessing the quality of life and symptoms of patients with pheochromocytoma or paraganglioma.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00911729
The ClinicalTrials.gov registry entry for NCT00911729 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular Insight Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00911729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00911729 about?
NCT00911729 is a clinical study titled "Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma". The purpose of this qualitative study is to evaluate the clarity and comprehensiveness of two disease-specific questionnaires, and to evaluate how effective these questionnaires are at assessing the quality of life and symptoms of patients with pheochromocytoma or paraganglioma.
What is the current status of trial NCT00911729?
This trial is currently terminated. The enrollment target is 24 participants. The study started on 2009-04.
Who is sponsoring clinical trial NCT00911729?
This trial is sponsored by Molecular Insight Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.